Fuso Pharmaceutical Secures Overdraft Agreement Amid Legal Dispute

Confident Investing Starts Here:

An announcement from Fuso Pharmaceutical Industries,Ltd. ( (JP:4538) ) is now available.

Fuso Pharmaceutical Industries, Ltd. has entered into a special overdraft agreement with Sumitomo Mitsui Banking Corporation to secure mid- to long-term liquidity following a court ruling against them in a patent infringement lawsuit. This agreement, which is unsecured and has a contract limit of 8 billion yen, is intended to address financial obligations resulting from the judgment, although it will not affect the company’s financial forecast for the fiscal year ending March 31, 2026.

More about Fuso Pharmaceutical Industries,Ltd.

Fuso Pharmaceutical Industries, Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of pharmaceutical products. The company is listed on the Tokyo Stock Exchange Prime Market.

Average Trading Volume: 26,104

Technical Sentiment Signal: Sell

Current Market Cap: Yen18.84B

See more data about 4538 stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks’

Best Online Brokers

, and find the ideal broker for your trades.

Report an Issue

No Byline Policy

Editorial Guidelines

Corrections Policy

Source